Recent Advances in the Treatment of Neurodegenerative Disorders and Cognitive Dysfunction

Rosser, Anne
May 1996
Journal of Neurology, Neurosurgery & Psychiatry;May1996, Vol. 60 Issue 5, p597
Book Review
No abstract available.


Related Articles

  • Disease Modifying Agents for Huntington's Disease: What is on the Horizon? Clarke, H.; Feigin, A. // CNS Drugs;1999, Vol. 12 Issue 5, p383 

    Huntington's disease is an autosomal dominant neurodegenerative disorder characterised by abnormalities of motor function, cognition and behaviour. The striatum is particularly vulnerable to the disease process with selective loss of medium-sized spiny projection neurons and relative sparing of...

  • Emerging Pharmacotherapy for Cancer Patients with Cognitive Dysfunction. Davis, Justinq; Ahlberg, Fiona M.; Berk, Michael; Ashley, David M.; Khasraw, Mustafa // BMC Neurology;2013, Vol. 13 Issue 1, p1 

    Advances in the diagnosis and multi-modality treatment of cancer have increased survival rates for many cancer types leading to an increasing load of long-term sequelae of therapy, including that of cognitive dysfunction. The cytotoxic nature of chemotherapeutic agents may also reduce...

  • Parkinson’s Disease and Cognitive Impairment. Yang, Yang; Tang, Bei-sha; Guo, Ji-feng // Parkinson's Disease (20420080);12/12/2016, p1 

    Parkinson’s disease (PD) is a progressive neurodegenerative disease primarily characterized by the hallmarks of motor symptoms, such as tremor, bradykinesia, rigidity, and postural instability. However, through clinical investigations in patients and experimental findings in animal models...

  • The Safety, Tolerability, Pharmacokinetics and Cognitive Effects of GSK239512, a Selective Histamine H3 Receptor Antagonist in Patients with Mild to Moderate Alzheimer. Nathan, Pradeep J.; Boardley, Rebecca; Scott, Nicola; Berges, Alienor; Maruff, Paul; Sivananthan, Tharani; Upton, Neil; Lowy, Martin T.; Nestor, Peter J.; Lai, Robert // Current Alzheimer Research;Mar2013, Vol. 10 Issue 3, p240 

    Background: The histamine H3 receptor plays a critical role in the negative neuromodulation of neurotransmitters involved in cognitive function. H3 receptor antagonists/inverse agonists have been shown to exert pro-cognitive effects in pre-clinical models. GSK239512 is a potent and selective H3...

  • The emerging role of norepinephrine in cognitive dysfunctions of Parkinson's disease. Vazey, Elena M.; Aston-Jones, Gary // Frontiers in Behavioral Neuroscience;Jul2012, Vol. 6, p1 

    Parkinson's disease (PD) is the second most common neurodegenerative disorder, affecting 1% of the population over age 60. In those patients cognitive dysfunction is a persistent issue that impairs quality of life and productivity. Neuropathological studies demonstrate significant damage in...

  • Neuroprotection and Drugs Used to Treat Psychiatric Disorders. Jantzie, Lauren L.; Todd, Kathryn G.; Baker, Glen B. // Child & Adolescent Psychopharmacology News;2007, Vol. 12 Issue 4, p1 

    The article examines the drugs used in treating psychiatric disorders. The pathoetiologies of neuropsychiatric disorders are investigated. Recent advances in the pathophysiology of schizophrenia suggests that this disorder has features of abnormal neuronal information, apoptosis and oxidative...

  • The Interaction between Obstructive Sleep Apnea and Parkinson’s Disease: Possible Mechanisms and Implications for Cognitive Function. Kaminska, Marta; Lafontaine, Anne-Louise; Kimoff, R. John // Parkinson's Disease (20420080);10/5/2015, Vol. 2015, p1 

    Parkinson’s disease (PD) is a relentlessly progressive neurodegenerative disorder associated with hallmark motor and nonmotor symptoms (NMS) such as sleep disturbances and cognitive dysfunction. While dopaminergic treatments have improved the motor aspects of PD, progression remains...

  • Alzheimerio ligos ir cukrinio diabeto ryÅ¡ys. Ramanauskaitė, G.; Audronytė, E.; Kaubrys, G. // Neurologijos Seminarai;2016, Vol. 20 Issue 4, p186 

    Alzheimer's disease is a chronic progressive neurodegenerative disorder which affects memory and other cognitive functions. Millions of elderly people around the world suffer from this disease and the number of patients is increasingly growing. Studies on pathogenesis of Alzheimer's disease have...

  • Multi-Target Directed Drugs: A Modern Approach for Design of New Drugs for the treatment of Alzheimerµs Disease. Tranches Dias, Kris Simone; Viegas, Claudio // Current Neuropharmacology;May2014, Vol. 12 Issue 3, p239 

    Alzheimer's disease (AD) is a complex neurodegenerative disorder with a multi-faceted pathogenesis. So far, the therapeutic paradigm "one-compound-one-target" has failed and despite enormous efforts to elucidate the pathophysiology of AD, the disease is still incurable.; The multiple factors...

  • Recent study on primary familial brain calcification. CHEN You; CEN Zhi-dong; LUO Wei // Chinese Journal of Contemporary Neurology & Neurosurgery;Jul2017, Vol. 17 Issue 7, p484 

    Primary familial brain calcification (PFBC), characterized by bilateral, symmetric calcifications in basal ganglia and other brain regions and visualized in neuroimaging and neuropsychiatric manifestations variable in type and severity, is a neurodegenerative disorder with clinical and genetic...


Read the Article


Sign out of this library

Other Topics